Beijing Huaxia Sangsheng Pharmaceutical

Beijing Huaxia Sangsheng Pharmaceutical is a specialized biopharmaceutical firm based in China that focuses on the development of botanical-based therapeutics derived from Traditional Chinese Medicine (TCM). The company is particularly recognized for its research into mulberry (Morus alba) extracts and their application in treating metabolic syndromes. Its product portfolio includes standardized herbal formulations targeting hyperlipidemia, diabetes, and cardiovascular health. By combining traditional knowledge with modern extraction and purification technologies, the company provides natural alternatives for chronic disease management. Huaxia Sangsheng maintains a strong presence in the Chinese domestic market through its specialized pharmaceutical and health supplement offerings. The company's research efforts are centered on validating the pharmacological efficacy of plant-derived compounds through clinical observation and standardized manufacturing.